Duchenne muscular dystrophy
4 stories related to this topic, newest first.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Roche to Run New Elevidys Trial for European Approval; FDA Plans Advisory Panels on Compounded Peptides
Roche announced a new trial of Elevidys, Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, to pursue approval in Europe. Meanwhile, the FDA will hold advisory panel meetings starting July 2026 to reconsider restrictions on compounded peptides.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Biotech Developments Include Duchenne Drug Class, Gilead Acquisitions and Industry Updates
A class of drugs for Duchenne muscular dystrophy has drawn attention in recent discussions. Gilead Sciences continues its series of mergers and acquisitions in the biotech sector. Additional news covers ongoing advancements and regulatory matters in biotechnology.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Elevidys Gene Therapy Shows Positive Results in Duchenne Muscular Dystrophy Trial
Sarepta Therapeutics reported positive topline results from a phase 3 trial of its gene therapy Elevidys for Duchenne muscular dystrophy. The trial met its primary endpoint of improved motor function in patients aged 4 to 7. The Duchenne muscular dystrophy field has experienced s…
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Recent Health News Highlights Breakthrough in Duchenne Treatment and Insulin Price Cap
A new therapy shows promise for Duchenne muscular dystrophy patients. Insulin prices are capped at $35 for many users. Additional evidence supports over-the-counter availability of abortion medications.